Perioperative tislelizumab with four cycles of neoadjuvant chemotherapy for resectable locally advanced esophageal squamous cell carcinoma: a phase 2 study

BackgroundThe application of neoadjuvant immunotherapy in the treatment of esophageal cancer needs further exploration. This study aimed to investigate the safety and effectiveness of tislelizumab, an anti-PD-1 antibody, combined with chemotherapy as neoadjuvant treatment for locally advanced esopha...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Na Zhou, Yuwei Hua, Yuping Ge, Qiang Wang, Chenyu Wang, Jia He, Luo Zhao, Shuangni Yu, Junfang Yan, Lin Zhao, Li Li, Chunmei Bai
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Frontiers Media S.A. 2024-12-01
Serie:	Frontiers in Immunology
Soggetti:	esophageal squamous cell carcinoma perioperative treatment tislelizumab immunotherapy neoadjuvant chemotherapy
Accesso online:	https://www.frontiersin.org/articles/10.3389/fimmu.2024.1482005/full
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!